Shangzi Wang
Overview
Explore the profile of Shangzi Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Li M, Chen Y, Wang S, Wang D, Suo C, et al.
Biol Sex Differ
. 2024 Dec;
15(1):106.
PMID: 39716176
Background: DNA methylation (DNAm) influences both sex differences and cancer development, yet the mechanisms connecting these factors remain unclear. Methods: Utilizing data from The Cancer Genome Atlas, we conducted a...
2.
Song Y, Li F, Wang S, Wang Y, Lai C, Chen L, et al.
Genome Res
. 2024 Oct;
34(10):1514-1527.
PMID: 39424324
As a major type of structural variants, tandem duplication plays a critical role in tumorigenesis by increasing oncogene dosage. Recent work has revealed that noncoding enhancers are also affected by...
3.
Gong B, Li D, Zhang Y, Kusko R, Lababidi S, Cao Z, et al.
Sci Rep
. 2024 Mar;
14(1):7028.
PMID: 38528062
Accurate indel calling plays an important role in precision medicine. A benchmarking indel set is essential for thoroughly evaluating the indel calling performance of bioinformatics pipelines. A reference sample with...
4.
Wang D, Dai J, Suo C, Wang S, Zhang Y, Chen X
Front Genet
. 2022 Nov;
13:1033214.
PMID: 36425064
The tumor heterogeneity of the transcriptional profiles is independent of genetic variation. Several studies have successfully identified esophageal squamous cell carcinoma (ESCC) subtypes based on the somatic mutation profile and...
5.
Fitzgerald A, Wang S, Agarwal V, Marcisak E, Zuo A, Jablonski S, et al.
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34737215
Background: Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer death in the USA by 2030. Immune checkpoint inhibitors fail to control most PDAC tumors...
6.
Zheng Y, Li B, Pan D, Cao J, Zhang J, Wang X, et al.
Breast Cancer Res
. 2021 May;
23(1):53.
PMID: 33933153
We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast...
7.
Gong B, Li D, Kusko R, Novoradovskaya N, Zhang Y, Wang S, et al.
Genome Biol
. 2021 Apr;
22(1):109.
PMID: 33863344
Background: Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence...
8.
Ajina R, Malchiodi Z, Fitzgerald A, Zuo A, Wang S, Moussa M, et al.
Cancer Immunol Res
. 2021 Jan;
9(4):386-400.
PMID: 33509790
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States. Pancreatic tumors are minimally infiltrated by T cells and are largely refractory to immunotherapy....
9.
Osborne N, Sundseth R, Gay M, Cao H, Tucker R, Nadella S, et al.
Am J Physiol Gastrointest Liver Physiol
. 2019 Aug;
317(5):G682-G693.
PMID: 31433212
Growth of pancreatic cancer is stimulated by gastrin in both a paracrine and an autocrine fashion. Traditional therapies have not significantly improved survival, and recently pancreatic cancer has been deemed...
10.
Smith J, Wang S, Nadella S, Jablonski S, Weiner L
Cancer Immunol Immunother
. 2017 Oct;
67(2):195-207.
PMID: 29043413
Advanced pancreatic ductal adenocarcinoma (PDAC) has typically been resistant to chemotherapy and immunotherapy; therefore, novel strategies are needed to enhance therapeutic response. Cholecystokinin (CCK) has been shown to stimulate growth...